Navigation Links
Luminex MAGPIX System Shown to be More Cost Effective and Efficient Than Conventional ELISA Method in Initial Study
Date:9/8/2010

AUSTIN, Texas, Sept. 8 /PRNewswire-FirstCall/ -- Luminex Corporation (Nasdaq: LMNX), today announced that initial results from a study conducted at the NMI Natural and Medical Sciences Institute at the University of Tubingen in Germany demonstrate that its MAGPIX® system provides more cost effective and efficient results than a conventional microtiter plate based ELISA method.

(Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100104/LUMINEXLOGO)

"These initial results demonstrate why MAGPIX could be a good choice for every research laboratory," said Dr. Thomas Joos, the head of the Biochemistry Department at the Natural and Medical Sciences Institute. "The system is a great choice for labs seeking one platform that allows the efficiency of multiplexing as well as the ability to run single tests, as needed. It can help labs save resources, increase efficiency and maximize results."

The NMI Natural and Medical Sciences Institute performed a comparative study between the recently launched MAGPIX system and a conventional ELISA method.  The study utilized an assay for soluble tumor necrosis factor receptor II to compare the analytical methods using several parameters including optimal detection antibody concentration, dynamic range and assay sensitivity, sample measurement, intra- and inter-assay precision, parallelism, and dilution linearity.  In addition to analytical performance, a time and motion analysis, and a cost comparison was performed.

The findings from this initial study demonstrate that MAGPIX provides accurate assay results at costs of as much as half of the microtiter plate ELISA method with equivalent sensitivity. While total assay and hands-on time for MAGPIX and ELISA were similar, MAGPIX is capable of producing up to 50 results in the same amount of time as one ELISA sample while requiring the same amount of sample material.

"We are very pleased with the findings of Dr. Joos's study at NMI, demonstrating strong performance of MAGPIX in relation to conventional ELISA testing," said Patrick J. Balthrop, president and CEO of Luminex.  "These initial data highlight the importance of MAGPIX as a scientific tool for any lab seeking to enhance productivity and bring the power of multiplexing to their day-to-day research."

Luminex's MAGPIX system is a compact analytical instrument capable of performing up to 50 tests on a single sample providing nearly 5,000 data points in under an hour. The easy-to-use and simple-to-deploy instrument was designed to meet the needs of scientists and researchers who have not been able to take advantage of the power of multiplexing because of resource or space limitations.

Based on Luminex's xMAP® Technology, MAGPIX provides fast, accurate and easily reproducible results and saves laboratory time and resources.  Like all of Luminex's instruments, it is versatile and flexible and can be used to analyze both nucleic acids and proteins, making it applicable in many research settings.

For more information on MAGPIX, call 512.219.8020, or visit www.luminexcorp.com/magpix.

About Luminex CorporationLuminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries. The Company's xMAP® multiplex solutions include an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics markets. The Company's xMAP Technology is sold worldwide and is already in use in leading clinical laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or xMAP Technology can be obtained at www.luminexcorp.com.Luminex Contacts:Harriss T. Currie, 512-219-8020Vice President, Finance and Chief Financial Officerhcurrie@luminexcorp.comMimi L. Torrington, 512-219-8020Director of Investor Relationsmtorrington@luminexcorp.comMedia:Nicole L. Cottrill, 615-327-7999ncottrill@seigenthaler.com
'/>"/>

SOURCE Luminex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Luminex Donates Companys First MAGPIX Multiplexing System to Papua New Guinea Institute of Medical Research
2. Luminex Announces Commercial Launch of New Cystic Fibrosis Test
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. CardioFocus Endoscopic Ablation System Earns CE Mark to Treat Atrial Fibrillation; US Clinical Investigation Underway
5. Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission
6. Syndicom SpineConnect Web Platform Chosen for Applied Spines Leg and Back Pain Clinical Trial of Its Stabilimax NZ(R) Dynamic Spine Stabilization System
7. Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System
8. New Topical Therapy Safely Treats Serious Skin Infections Without Systemic Side Effects
9. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
10. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
11. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... Md. , May 10, 2017 CSSi, ... solutions for the clinical research industry, is proud to ... www.CSSiEnroll.com . The new website features both enriched content ... user experience and enhances the company,s already well-established position ... industry. "After many months of hard ...
(Date:5/9/2017)... , May 9, 2017  Semler Scientific, ... provides technology solutions to improve the clinical effectiveness ... results for the first quarter ended March 31, ... products enable our customers to identify when preventive ... intervene before events like heart attacks or strokes ...
(Date:5/6/2017)... , May 5, 2017  May is Stroke ... one of the most important methods to prevent a ... the Centers for Disease Control and Prevention, undetected and ... 1 Omron, the global leader in personal heart ... the elimination of heart attack and stroke and is ...
Breaking Medicine Technology:
(Date:5/29/2017)... ... 2017 , ... A New York high tech innovator and a Canadian not-for-profit ... of Artificial Intelligence (AI) in helping nudge men forward to be more proactive about ... of the Canadian Men’s Health Foundation (CMHF), whose mission is to inspire men to ...
(Date:5/28/2017)... ... ... HYPERAMS, LLC announced it will perform the inventory liquidation of ... The sale began this week and the inventory is expected to sell quickly. ... medical accessories, including blood pressure cuffs, stethoscopes, CPR masks, as well as blank polos, ...
(Date:5/28/2017)... ... 28, 2017 , ... Viewers likely know Rob Lowe from such 80s hits ... for his work on NBC’s The West Wing and Parks and Recreation. But recently, ... “Informed,” which puts the spotlight on important modern-day issues that face today’s society. One ...
(Date:5/27/2017)... ... ... In any business, follow up is critical to success. It is the same ... there will always be some patients who can’t or won’t make a immediate decision. ... it comes to presenting treatment. After the patient leaves, most practices end up ...
(Date:5/26/2017)... NY (PRWEB) , ... May 26, 2017 , ... Mediaplanet ... & Wound Care" campaign in USA Today, which will educate readers on how to ... of the campaign, a large focus is placed on melanoma. Dancing with the Stars ...
Breaking Medicine News(10 mins):